Introduction
Prostate cancer (PCa) remains a leading cause of cancer-related mortality in men. While initial treatments like Androgen Deprivation Therapy (ADT) are often effective, many patients eventually progress to Castration-Resistant Prostate Cancer (CRPC). At this stage, tumors frequently become insensitive to standard Androgen Receptor Signaling Inhibitors (ARSIs) like enzalutamide. Recent research has highlighted "metabolic reprogramming" as a key driver of this progression, where PCa cells shift toward increased mitochondrial oxidative phosphorylation (OXPHOS) to fuel their growth. This study identifies the $m^6A$-modified circular RNA circRBM33 as a master regulator of this metabolic shift and a potential therapeutic target.
Identification and m6A Modification of circRBM33
To uncover the epigenetic drivers of PCa progression, researchers integrated public circRNA-seq data with $m^6A$-RNA Immunoprecipitation (MeRIP) sequencing. This multi-omics approach identified circRBM33 as a highly expressed, $m^6A$-modified circular RNA associated with poor clinical outcomes.
The circular nature of circRBM33 was confirmed through RNase R digestion and Actinomycin D treatment, which demonstrated its superior stability compared to linear transcripts. The study found that the $m^6A$ modification, added by the "writer" enzyme METTL3, acts as a molecular switch that enables circRBM33 to interact with the "reader" protein FMR1.
The circRBM33-FMR1-PDHA1 Axis
Unlike many circRNAs that act as miRNA sponges, circRBM33 functions as a protein scaffold. It recruits FMR1 to the mRNA of PDHA1 (Pyruvate Dehydrogenase E1 Subunit Alpha 1), a critical enzyme linking glycolysis to the tricarboxylic acid (TCA) cycle. By forming this complex, circRBM33 stabilizes PDHA1 mRNA, extending its half-life and significantly boosting mitochondrial respiration. This "supercharging" of the mitochondria increases the production of Acetyl-CoA and ATP, providing the energy necessary for rapid tumor growth and invasion.
Key Results and Clinical Significance
Clinical analysis revealed that high circRBM33 expression is strongly associated with higher Gleason scores and significantly shorter biochemical recurrence-free survival in patients.
Functional assays showed that silencing circRBM33 reduced ATP production and the NADH/NAD+ ratio, effectively slowing tumor metabolism. Most importantly, the study found that circRBM33 regulates the expression of AR-V7, a splice variant of the androgen receptor that drives resistance to enzalutamide. In mouse models, knocking down circRBM33 restored sensitivity to ARSI therapy, with the combination of circRBM33 silencing and enzalutamide producing a synergistic reduction in tumor volume.
Conclusion
The discovery of the $m^6A$-modified circRBM33-FMR1-PDHA1 axis provides a new understanding of how metabolic reprogramming drives prostate cancer progression and drug resistance. Targeting this axis, perhaps through antisense oligonucleotides (ASOs) or small molecules that disrupt the circRBM33-FMR1 interface, offers a promising strategy for treating advanced, therapy-resistant prostate cancer.
Summary updated